

PCTWORLD INTELLECTUAL
PROPERTY ORGANIZATION
Internation

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁶ : C12Q 1/68, C12P 19/34, C07H 21/04		A1	(11) International Publication Number: WO 96/02668
			(43) International Publication Date: 1 February 1996 (01.02.96)
(21) International Application Number: PCT/CA95/00423 (22) International Filing Date: 13 July 1995 (13.07.95) (30) Priority Data: 08/275,250 15 July 1994 (15.07.94) US (60) Parent Application or Grant (63) Related by Continuation US 08/275,250 (CIP) Filed on 15 July 1994 (15.07.94) (71) Applicant (for all designated States except US): CANGENE CORPORATION [CA/CA]; 6280 Northwest Drive, Mississauga, Ontario L4V 1J4 (CA). (72) Inventor; and (75) Inventor/Applicant (for US only): SOOKNANAN, Roy [CA/CA]; 254 Glebe Mount Avenue, Toronto, Ontario M4C 3T6 (CA). (74) Agent: McMAHON, Eileen; Deeth Williams Wall, Suite 400, National Bank Building, 150 York Street, Toronto, Ontario M5H 3S5 (CA).			(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: USE OF RNA POLYMERASE TO IMPROVE NUCLEIC ACID AMPLIFICATION PROCESS			
(57) Abstract This invention relates to the use of a eukaryotic or prokaryotic DNA- directed RNA polymerase of a class that synthesizes cellular RNA, in a process for the amplification of a specific nucleic acid sequence or of its complement. It also relates to a new process for amplifying a specific nucleic acid sequence. The process includes one or more reactions which may take place in a single reaction vessel. In one instance, in a first reaction, the process includes providing a first RNA polymerase which uses a DNA first template to synthesize an RNA first template, and, in a second reaction, providing the RNA first template and a number of other reagents such that the reagents use the RNA first template to synthesize a DNA second template and an RNA second template. Thereafter a cycle ensues in which the reagents use the RNA second template to synthesize a DNA third template and multiple copies of the RNA second template. The RNA second template is the specific nucleic acid sequence or its complement. This invention includes a kit containing the reagents of this invention.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

USE OF RNA POLYMERASE TO IMPROVE NUCLEIC ACID AMPLIFICATION PROCESS

Field of the Invention

This invention relates to the use of DNA-directed RNA polymerase of a
5 class that synthesizes cellular RNA to improve a process of amplifying a
specific nucleic acid sequence.

Background of the Invention

The presence of nucleic acids in a sample may indicate that a source
from which the sample is taken has a disease, disorder or abnormal physical
10 state. Certain diagnostics determine whether nucleic acids are present in a
sample. These diagnostics invariably require amplification of nucleic acids
because of the copy number problem.

In a virus or cell, for example, there is usually a single copy of a
particular gene. Without amplification of specific nucleic acids of the gene, it is
15 often difficult to detect the presence of the nucleic acids.

There are a number of processes for amplifying nucleic acids. Two such
processes are those described in United States Patent No. 5,130,238 (Malek et
al.) and United States Patent No. 5,409,818 (Malek et al.). Malek's
amplification processes require less participation and fewer manipulations by
20 the user. The amplification cycle takes place at a relatively constant ambient
temperature and without the serial addition of reagents. The template nucleic
acid sequence generates more than one product from one substrate in each
cycle of the amplification process. The amplification processes use either DNA
or RNA as a starting template.

25 Where single or double-stranded DNA is the starting template, Malek's
processes require thermal or alkali denaturation before the amplification cycle.

Where single-stranded DNA is a starting template, a first primer
hybridizes to the DNA. Then, a DNA-directed DNA polymerase makes a
double-stranded DNA product. The product of the polymerization then

undergoes either thermal or alkali denaturation before the single-stranded DNA enters the cycle.

Where double-stranded DNA is a starting template, the double-stranded DNA first undergoes either thermal or alkali denaturation. The first primer then
5 hybridizes to one of the single strands of DNA. Then, a DNA-directed DNA polymerase makes a double-stranded DNA product. The product of the polymerization then undergoes a second thermal or alkali denaturation before the single-stranded DNA enters the cycle.

Thermal denaturation is problematic because entry into the amplification
10 cycle is not isothermal. Alkali denaturation is problematic because it requires participation and manipulations by a user of the amplification process. Thermal denaturation may be used not only in Malek's processes, but in other amplification processes (for example, PCR and LCR).

Thus, a need exists for improvements to nucleic acid amplification to (1)
15 decrease the number of steps involved in the process, (2) decrease the participation and manipulations by a user, (3) eliminate the heating steps involved in entering any amplification cycle, and (4) reduce the temperatures at which any heating takes place.

In this application, the phrase "specific nucleic acid sequence" means a
20 sequence of single-stranded or double-stranded nucleic acids or a sequence complementary to such sequence which one wishes to amplify. "DNA-directed RNA polymerase" means such polymerase of a quality suitable for use in molecular biological reactions. One "unit" of a first RNA polymerase means the amount of RNA polymerase which catalyzes the incorporation of one nanomole
25 of radiolabelled ribonucleoside triphosphate into an RNA first template in 10 minutes at 37°C.

Summary of the Invention

This invention makes the amplification of nucleic acids more expedient, requiring less participation and fewer manipulations than conventional

amplification processes. In one instance, the amplification, including the entry into any amplification cycle, takes place at a relatively constant ambient temperature. The entry into the cycle does not require serial steps.

This invention relates to the use of a eukaryotic or prokaryotic DNA-directed RNA polymerase of a class that synthesizes cellular RNA, in a process
5 for the amplification of a specific nucleic acid sequence. In one instance, the polymerase is *Escherichia coli* RNA polymerase. The use may also include the use of an inhibitor of such polymerase.

This invention also relates to a process for the amplification of a specific
10 nucleic acid sequence. In one instance, the process includes two steps (A)-(B).

Step (A) - In Step (A), one provides one or more reaction vessels containing reagents including, a DNA first template; a first RNA polymerase which is a eukaryotic or prokaryotic RNA polymerase of a class that synthesizes cellular RNA; ribonucleoside triphosphates; deoxyribonucleoside
15 triphosphates; a first oligonucleotide primer having a plus sequence of a promoter recognised by a second RNA polymerase; a second oligonucleotide primer; a second RNA polymerase which is a DNA-directed RNA polymerase that recognizes the promoter; an RNA-directed DNA polymerase; a DNA-directed DNA polymerase; a ribonuclease that hydrolyzes RNA of an RNA-
20 DNA hybrid without hydrolyzing single or double-stranded RNA or DNA. The reagents may be combined in a variety of ways to provide one or more reaction mediums. A single reaction vessel may be used for the reactions.

In the process, (1) the first RNA polymerase uses the DNA first template to synthesize an RNA first template which includes the specific nucleic acid
25 sequence or a sequence complementary to the specific nucleic acid sequence, (2) the first oligonucleotide primer hybridizes to the RNA first template, (3) the RNA-directed DNA polymerase uses the RNA first template to synthesize a DNA second template by extension of the first oligonucleotide primer and thereby forms an RNA-DNA hybrid intermediate, (4) the

ribonuclease hydrolyzes RNA of the RNA-DNA hybrid intermediate, (5) the second oligonucleotide primer hybridizes to the DNA second template, (6) the DNA-directed DNA polymerase uses the second oligonucleotide primer and the DNA second template to synthesize a functional promoter recognized by the second RNA polymerase, and (7) the second RNA polymerase recognizes the functional promoter and transcribes the DNA second template, thereby providing copies of an RNA second template.

Thereafter, a cycle ensues. In the cycle, (1) the second oligonucleotide primer hybridizes to the RNA second template, (2) the RNA-directed DNA polymerase uses the RNA second template to synthesize a DNA third template by extension of the second oligonucleotide primer and thereby forms an RNA-DNA hybrid intermediate, (3) the ribonuclease hydrolyzes RNA of the RNA-DNA hybrid intermediate, (4) the first oligonucleotide primer hybridizes to the DNA third template, (5) the DNA-directed DNA polymerase uses the first oligonucleotide primer as template to synthesize a functional promoter recognized by the second RNA polymerase by extension of the DNA third template, and (6) the second RNA polymerase recognizes the functional promoter and transcribes the DNA third template, thereby providing copies of the RNA second template.

Step (B) - In Step (B), one maintains the conditions for a time sufficient to achieve a desired amplification of the specific nucleic acid sequence or of a sequence complementary to the specific nucleic acid sequence.

In another instance, the process includes three Steps (A)-(C). The process (all of Steps (A)-(C)) may take place in one or more reaction vessels.

Step (A) In Step (A), one provides reagents including, (i) a DNA first template, (ii) a first RNA polymerase which is a eukaryotic or prokaryotic RNA polymerase, the polymerase being of a class that synthesizes cellular RNA, and (iii) ribonucleoside triphosphates. The RNA polymerase uses the DNA first template to synthesize an RNA first template which includes the specific nucleic

acid sequence. The DNA first template could be double-stranded DNA or single-stranded DNA. The first RNA polymerase may be *Escherichia coli* RNA polymerase. The concentration of *Escherichia coli* RNA polymerase could be in the range of, but not limited to, 0.04-0.2 units per μ l.

5 Step (B) In Step (B), one provides in one or more steps reagents including (i) a first oligonucleotide primer having a plus sequence of a promoter recognised by a second RNA polymerase, (ii) a second oligonucleotide primer, (iii) a second RNA polymerase which is a DNA-directed RNA polymerase that recognizes the promoter, (iv) an RNA-directed DNA polymerase, (v) a DNA-
10 directed DNA polymerase, (vi) a ribonuclease that hydrolyzes RNA of an RNA-DNA hybrid without hydrolyzing single or double-stranded RNA or DNA, (vii) ribonucleoside and deoxyribonucleoside triphosphates, and (viii) the RNA first template, under conditions such that (1) the first oligonucleotide primer hybridizes to the RNA first template, (2) the RNA-directed DNA polymerase
15 uses the RNA first template to synthesize a DNA second template by extension of the first oligonucleotide primer and thereby forms an RNA-DNA hybrid intermediate, (3) the ribonuclease hydrolyzes RNA of the RNA-DNA hybrid intermediate, (4) the second oligonucleotide primer hybridizes to the DNA second template, (5) the DNA-directed DNA polymerase uses the second
20 oligonucleotide primer and the DNA second template to synthesize a functional promoter recognized by the second RNA polymerase, and (6) the second RNA polymerase recognizes the functional promoter and transcribes the DNA second template, thereby providing an RNA second template.

Thereafter, a cycle ensues. In the cycle, (1) the second oligonucleotide
25 primer hybridizes to the RNA second template, (2) the RNA-directed DNA polymerase uses the RNA second template to synthesize a DNA third template by extension of the second oligonucleotide primer and thereby forms an RNA-DNA hybrid intermediate, (3) the ribonuclease hydrolyzes RNA of the RNA-DNA hybrid intermediate, (4) the first oligonucleotide primer hybridizes to the
30 DNA third template, (5) the DNA-directed DNA polymerase uses the first oligonucleotide primer as template to synthesize a functional promoter

recognized by the second RNA polymerase by extension of the DNA third template, and (6) the second RNA polymerase recognizes the functional promoter and transcribes the DNA third template, thereby providing copies of an RNA second template.

- 5 Step (C) Thereafter, in Step (C), one maintains the conditions for a time sufficient to achieve a desired amplification of the specific nucleic acid sequence or of a sequence complementary to the specific nucleic acid sequence. For example, one may maintain the conditions for a time between, but not limited to, 30 minutes and 4 hours.

10 In Step (A), one could also provide deoxyribonucleoside triphosphates. In such a situation, the deoxyribonucleoside triphosphates and the ribonucleoside triphosphates need not be added to the second reaction medium.

 In Step (B), one could also provide an inhibitor of the first RNA
15 polymerase. In one case, the inhibitor is rifampicin which is provided at a concentration in the range of, but not limited to, 10-100 µg per ml. In the alternative, rather than using an inhibitor of the first RNA polymerase, Step (A) could be followed by heating the first reaction medium to about 65°C before Step (B).

20 In Step (A) or (B), one could also provide an alkylated sulfoxide and a suitable carrier protein. The alkyl sulfoxide may be dimethylsulfoxide (DMSO) and the carrier protein may be bovine serum albumin (BSA).

 The first oligonucleotide primer may also include a plus sequence of a transcription initiation site for the second RNA polymerase. The plus sequence
25 of the transcription initiation site would be operatively linked to the plus sequence of the promoter. The first RNA polymerase could be any prokaryotic RNA polymerase, such as *E. coli* RNA polymerase, an RNA polymerase of *Bacillus* or of *Archae* bacteria. The first RNA polymerase could be any eukaryotic RNA polymerase, such as RNA polymerase I, RNA polymerase II, or
30 RNA polymerase III. The second RNA polymerase could be bacteriophage T7

RNA polymerase. In such a case, the plus sequence of the transcription initiation site and the plus sequence of the promoter together are the nucleotide sequence:

5'- AATTCTAATACGACTCACTATAGGGAGA - 3'

5 The process may include a further step of monitoring the reaction medium for consumption of any of the first primer, second primer, ribonucleoside and deoxyribunucleoside triphosphates or for accumulation of any product of the cycle. The monitoring step could be (1) detecting a nucleic acid product of the cycle using a nucleic acid probe, or restriction
10 endonucleases and electrophoretic separation, (2) monitoring the accumulation of the RNA second template, (3) monitoring the accumulation of the DNA second template, (4) monitoring DNA containing a functional promoter recognized by the RNA polymerase, (5) monitoring the accumulation of the RNA-DNA hybrid intermediate, (6) monitoring consumption of any first primer,
15 second primer, ribonucleoside and deoxyribunucleoside triphosphates or accumulation of any product of the cycle with a value representing consumption of the reagent or accumulation of the product in the second reaction medium in the absence of the specific nucleic acid sequence.

 In the process, the ribonuclease could be *Escherichia coli* ribonuclease
20 H or calf thymus ribonuclease H. The first oligonucleotide primer or the second oligonucleotide primer could be bound reversibly to an immobilized support. The DNA-directed RNA polymerase could be bacteriophage RNA polymerase, bacteriophage T7 RNA polymerase, bacteriophage T3 polymerase, bacteriophage Φ II polymerase, *Salmonella* bacteriophage sp6 polymerase, or
25 *Pseudomonas* bacteriophage gh-1 polymerase. The RNA-directed DNA polymerase could be retrovirus reverse transcriptase such as an avian myeloblastosis virus polymerase or a Moloney murine leukemia virus polymerase.

 In one instance, the DNA-directed DNA polymerase lacks DNA
30 exonuclease activity. In another instance, all DNA polymerases in the second

reaction medium lack DNA exonuclease and DNA endonuclease activity. The DNA-directed DNA polymerase could be avian myeloblastosis virus polymerase, DNA polymerase α or DNA polymerase β , or calf thymus DNA polymerase.

5 The process may include the steps of ligating a DNA product of the cycle into a cloning vector and then cloning the DNA product, expressing a product encoded by the DNA product of the cycle in an expression system.

 The invention includes a kit for amplifying nucleic acid sequences. The kit includes one or more receptacles containing (a) a first RNA polymerase
10 which is a DNA-directed RNA polymerase which synthesizes cellular RNA, (b) ribonucleoside triphosphates, (c) deoxyribonucleoside triphosphates, (d) a first oligonucleotide primer including a plus sequence of a promoter recognized by a second RNA polymerase, (e) a second oligonucleotide primer, (f) a second RNA polymerase which is a DNA-directed RNA polymerase that recognizes the
15 promoter, (g) an RNA-directed DNA polymerase, (h) a DNA-directed DNA polymerase, and (i) a ribonuclease that hydrolyzes RNA of an RNA-DNA hybrid without hydrolyzing single- or double-stranded RNA or DNA.

 In the kit, the first RNA polymerase may be *Escherichia coli* RNA polymerase. The kit may also include a receptacle containing an inhibitor of
20 *Escherichia coli* RNA polymerase. In one instance, the inhibitor is rifampicin.

 The kit may also include a receptacle containing an alkylated sulfoxide and a receptacle containing a suitable carrier protein.

Brief Description of the Drawings

 In drawings which illustrate embodiments of the invention,

25 Figure 1 is a general illustration of a nucleic acid amplification process starting with double-stranded DNA or with single-stranded DNA.

 Figure 2 shows the sensitivity of transcripts generated by using *Escherichia coli* RNA polymerase and genomic DNA to RNase A and DNase I.

Figure 3A shows the inhibition of *Escherichia coli* RNA polymerase by rifampicin.

Figure 3B shows the effect of rifampicin in NASBA™ amplification. I shows an agarose gel containing ethidium bromide. II shows a northern blot hybridization.

Figure 4 shows the evidence for specific amplification from transcriptions generated from *Escherichia coli* RNA polymerase where 4A shows the results of an agarose gel containing ethidium bromide and 4B shows a northern blot hybridization.

Figure 5 shows the specific amplification of (I) GM-CSF and (II) G3PDH Sequences from transcripts generated using *Escherichia coli* RNA polymerase.

Figure 6 shows the amplification in NASBA™ of specific sequences of *Chlamydia trachomatis* from *Escherichia coli* RNA polymerase generated RNA, (I) PL1, and (II) VD1.

Figure 7 shows the amplification in NASBA™ of DNA transcribed with *Escherichia coli* RNA polymerase using a 2-step versus a 3 step procedure and a single reaction vessel.

Detailed Description of the Preferred Embodiments

This invention relates to the use of a eukaryotic or prokaryotic DNA-directed RNA polymerase which is of a class that synthesizes cellular RNA, in a process for the amplification of a specific nucleic acid sequence. In one embodiment, such polymerase is used in the amplification process which is described in United States Patent Number 5,409,818 (Malek et al.). In another embodiment, such polymerase is used in the amplification process which is described in United States Patent No. 5,130,238 (Malek et al.). In such embodiments, this invention relates to a novel process for entering the amplification cycle. In a further embodiment, the polymerase is used in the amplification process described in United States Patent No. 4,683,195 (Mullis),

United States Patent No. 4,683,202 (Mullis) and GenProbe U.S. Patent No. 5,399,491 (Kacian et al.).

By way of example, to a first reaction medium containing single-stranded or double-stranded DNA (DNA first template) suspected of containing or known to contain a specific nucleic acid sequence, one adds *Escherichia coli* RNA polymerase and ribonucleoside triphosphates. The *Escherichia coli* RNA polymerase non-specifically transcribes the DNA template independent of specific promoter sequences (Chamberlin, 1976; Ovchinnikov et al., 1977) to provide an RNA first template. One can use either *Escherichia coli* RNA polymerase holo or core enzyme, however, the core is preferred because of the increased promoter independent transcription due to the absence of the sigma factor.

Following transcription of the DNA first template, there is at least one RNA copy (an RNA first template) for each DNA first template. After obtaining the RNA first template, one provides a second set of reagents as described in the Summary of the Invention.

After providing these reagents, the first primer hybridizes to the RNA first template, the RNA-directed DNA polymerase uses the RNA first template to synthesize a DNA second template by extending the first primer, resulting in a RNA-DNA hybrid intermediate. The ribonuclease hydrolyzes RNA of the RNA-DNA hybrid. The second primer hybridizes to the DNA second template. The DNA-directed DNA polymerase uses the second primer and the DNA second template to synthesize a functional promoter recognized by the second RNA polymerase. The second RNA polymerase recognizes the functional promoter and transcribes the DNA second template providing copies of the RNA second template. The RNA second template then enters the cycle described in United States Patent No. 5,130,238 and in United States Patent No. 5,409,818 (Malek et al.) such that the process results in multiple copies of the specific nucleic acid sequence.

Thus, this improvement eliminates the need for DNA strand separation and first primer-primed extension of the DNA first template. The DNA first template is used in a single transcription reaction rather than in a separate priming reaction before amplification of a specific nucleic acid.

5 MATERIALS AND METHODS

Materials

Oligonucleotides were synthesized using an Applied Biosystems DNA synthesizer. Columns, phosphoramidites, and reagents used for oligonucleotide synthesis were purchased from Applied Biosystems, Inc.

10 Oligonucleotides were purified by polyacrylamide gel electrophoresis followed by DEAE cellulose chromatography. The radioisotope α - ^{32}P -CTP (~3000 Ci/mmol) and γ - ^{32}P -ATP (~3000 Ci/mmol) (was from Amersham. RNase A and rifampicin were purchased from Sigma. DNase I was obtained from Promega. *Escherichia coli* RNA polymerase was purchased from Boehringer Mannheim
15 and Epicentre Technologies Inc.

Isolation of DNA and sequencing

The purification of genomic DNA from KG-1 and *Salmonella typhimurium* cells was according to Sambrook et al., 1989. Total nucleic acids were isolated from *Chlamydia* infected HeLa cells according to Boom et al., 1990.

20 Agarose Gel Electrophoresis and Northern Blot Hybridization

Agarose gels were prepared and run according to Sambrook et al., 1989. The gels contained either 3% low-melt agarose (NuSieve™; FMC) and 1% agarose or only 2% agarose in 1X Tris-acetate EDTA (TAE) with 0.2 $\mu\text{g/ml}$ ethidium bromide. Aliquots (5 μl) of the amplification reactions were analysed.

25 Following electrophoresis, the amplified materials were transferred to a nylon membrane by electroblotting (Sambrook et al., 1989). The nucleic acids were fixed to the nylon membrane and hybridized to specific probes using conditions described by Sooknanan et al., 1993. The probes were labelled at the 5' - end with ^{32}P (Sambrook et al., 1989). Following hybridization and the

removal of non-specifically bound probe by washing, autoradiography was performed using Kodak XAR-5 film.

TCA Precipitation

Aliquots (5 μ l) of transcription reactions were TCA precipitated according to Sambrook et al., 1989. Radioactivity was determined in a liquid scintillation counter.

Example 1 Transcription of Native Genomic DNA *in vitro* using *Escherichia coli* RNA Polymerase

A standard *Escherichia coli* RNA polymerase transcription reaction comprised 66.67 mM Tris (pH 8.5), 83.3 mM KCl, 20 mM MgCl₂, 3.3 mM of each ATP, CTP, GTP and UTP, 1.6 mM of each dATP, dCTP, dGTP and dTTP, 5 μ g bovine serum albumin, 16.6 mM DTT, 7.5 units placental ribonuclease inhibitor, $\leq$ 500 ng double-stranded DNA and 1 unit *Escherichia coli* RNA polymerase core enzyme in a final volume of 15 μ l. The reaction mixture was incubated at 40°C for 30 minutes.

In order to demonstrate transcription of the DNA template by *Escherichia coli* RNA polymerase, aliquots of the transcription reactions were digested with either 2 μ g RNase A (RNA specific nuclease) or 2 units DNase I (DNA specific nuclease) at 37°C for 30 minutes and then analyzed on an ethidium bromide stained agarose gel. Figure 2, lanes A2 and B2 show the transcription products from 100 ng of native DNA isolated from human myeloid cell line KG-1 and *Salmonella typhimurium*, respectively. The transcription products were sensitive to RNase A (Figure 2, lanes A3 and B3) but not to DNase I (Figure 2, lanes A4 and B4) confirming that the synthesized product was RNA. DNase I digested the input DNA template as expected (Figure 2, lanes A4 and B4). In addition, the majority of the RNA synthesized appeared to be a heterogeneous mixture as indicated by the smear extending above the 1 Kb DNA molecular weight marker on the native ethidium bromide stained agarose gel.

In Figure 2, the following lanes have the following materials:

- A - 250 ng KG-1 genomic DNA
- B - 250 ng *Salmonella typhimurium* genomic DNA
- M - double-strand DNA molecular weight marker

- 5 1 - mock transcription reaction (no enzyme)
- 2 - untreated transcription reaction
- 3 - RNase A treated transcription reaction
- 4 - DNase I treated transcription reaction

10 **Example 2 Specific Inhibition of *Escherichia coli* RNA Polymerase without Inhibiting NASBA™**

Escherichia coli RNA polymerase must be inactivated following transcription to prevent the inhibition of NASBA™. *Escherichia coli* RNA polymerase reactions containing 1.7 pmoles α -³²P-CTP, 100 ng native genomic
15 DNA and 0, 1, 10 or 100 μ g/ml rifampicin were performed as described in Example 1.

 The levels of RNA synthesized were measured by TCA precipitation of the transcribed materials. Both 10 and 100 μ g/ml rifampicin were sufficient to inhibited 1 unit of *Escherichia coli* RNA polymerase resulting in less than 2%
20 RNA synthesis compared to 10% for 1 mg/ml rifampicin and 100% when no rifampicin was present (Figure 3A).

 On the other hand, rifampicin at either 10 μ g/ml or 100 μ g/ml concentrations did appear to inhibit NASBA™ reactions compared to no added rifampicin (Figure 3B). It was also possible to inactivate *Escherichia coli* RNA
25 polymerase by incubating the transcription reactions at 65°C for at least 2 minutes (data not shown).

 In Figure 3B, I shows an agarose gel containing ethidium bromide, II shows a northern blot hybridization.

 In Figure 3B, the following lanes have the following materials:

- 30 A - no rifampicin

- | | | | |
|---|-----|---|---|
| | B | - | 10 µg/ml rifampicin |
| | C | - | 100 µg/ml rifampicin |
| | M | - | double-strand DNA molecular weight marker |
| 5 | 1 | - | no added template |
| | 2,3 | - | 10 ng P1-primed genomic DNA as template |

Example 3 Evidence for Specific Amplification from RNA Transcribed by *Escherichia coli* RNA Polymerase from Double-strand DNA Template

10 Six separate transcription reactions each containing 10 ng of native human genomic DNA were performed as described in Example 1. The reactions were pooled and re-divided into 6 equal amounts for the purpose of standardization. Two of the aliquots were then digested with 2 µg RNase A each and another two with 2 units DNase I each as described in Example 1.

15 The final two aliquots were incubated as the others but without any added nuclease.

Following the incubation, the samples were deproteinized and the nucleic acids recovered after ethanol precipitation in 5 µl of sterile H₂O. Each 5 µl sample was then added to standard NASBA™ reactions containing GM-CSF

20 specific primers and allowed to amplify for 90 minutes at 40°C. In parallel, duplicate NASBA™ reactions each containing 10 ng of untreated native HGD were also performed.

The products contained in 5 µl aliquots of the amplification reactions were analyzed on an ethidium bromide stained agarose gel followed by

25 Northern blot hybridization. All of the reactions contained amplified materials based on ethidium bromide staining (Figure 4a, lanes 1-10) indicating that the amplification reactions were not inhibited. However, after hybridization with a probe specific for the amplified GM-CSF sequence, positive signals were seen only from reactions containing the undigested transcribed material (Figure 4b,

30 lanes 5, 6) and the DNase I digested material (Figure 4b, lanes 9, 10). The reactions containing either the native DNA or the RNase A digested material

were negative (Figure 4b, lanes 2, 3 and 7, 8 respectively). These results indicated that the GM-CSF specific amplification originated from RNA generated after transcription of native DNA by *Escherichia coli* RNA polymerase.

5 In Figure 4b, the following lanes have the following materials:

- | | | |
|--------|---|--|
| 1 | - | no added template |
| 2,3 | - | 10 ng native DNA as template |
| 4 | - | no added template |
| 5,6 | - | untreated transcription reaction as template |
| 10 7,8 | - | RNase A treated transcription reaction as template |
| 9,10 | - | DNase I treated transcription reaction as template |

15 **Example 4 Amplification in NASBA™ of Specific Sequences from RNA Generated after *Escherichia coli* RNA Polymerase Transcription of Human Genomic DNA (HGD)**

Escherichia coli RNA polymerase transcription reactions containing 1 ng, 10 ng or 100 ng of HGD were performed as described in Example 1. Following transcription, the appropriate primer mixture was added directly to the transcription reaction to give a final concentration in a 25 µl volume of 0.2 µM of the first primer (P1), 0.2 µM of the send primer (P2) and 15% (v/v) DMSO. The reaction mixture was heated at 65°C for 2 minutes and then transferred to 40°C. After 2 minutes at 40°C, an enzyme mixture containing 8 units AMV reverse transcriptase, 0.2 units RNase H, 40 units T7 RNA polymerase and 100 µg/ml BSA was added to each reaction and the final reaction volume adjusted to 25 ml with H₂O. The reactions were incubated at 40°C for an additional 90 minutes.

In parallel, 1 ng, 10 ng and 100 ng of HGD were denatured and P1 primed. The P1- primed DNA was separated by thermal denaturation and added to standard 25 µl NASBA™ reactions (40 mM Tris, pH 8.5, 50 mM KCl, 12 mM MgCl₂, 2 mM of each ATP, CTP, GTP and UTP, 1 mM of each dATP,

dCTP, dGTP and dTTP, 10 mM DTT, 8 units AMV reverse transcriptase, 0.2 units RNase H, 40 units T7 RNA polymerase and 100 µg/ml BSA) and incubated at 40°C for 90 minutes. A third set of standard NASBA™ reactions containing 1 ng, 10 ng or 100 ng of untreated native HGD as templates were
 5 also performed.

Following amplification, a 5 µl aliquot of each reaction was analyzed on an ethidium bromide stained agarose gel followed by Northern blot hybridization. The results for primers specific for GM-CSF and G3PDH sequences are shown in Figure 5 I and 5 II respectively. The ability to amplify
 10 specific DNA sequences from the RNA generated after transcription of the DNA with *Escherichia coli* RNA polymerase was the same when compared to the conventional P1-priming procedure (Figures 5 I and II, lanes C2-7 and B2-7 respectively). The untreated DNA gave no specific amplification for either primer set (Figure 5 I and II, lanes A2-7).

15 In Figure 5, the following lanes have the following materials:

A	-	untreated native DNA
B	-	P1-primed DNA
C	-	<i>Escherichia coli</i> RNA polymerase RNA from DNA

20	1	-	no template
	2,3	-	100 pg DNA
	4,5	-	1 ng DNA
	6,7	-	10 ng DNA

25 **Example 5 Amplification in NASBA™ of Specific Sequences from RNA Generated after *Escherichia coli* RNA Polymerase Transcription of *Chlamydia trachomatis* DNA; a Bacterial Model**

Escherichia coli RNA polymerase transcription reactions containing different amounts of total nucleic acids isolated from *Chlamydia trachomatis*
 30 infected HeLa cells were performed as described in Example 1. Primers

specific for the cryptic plasmid (PL1) and the MOMP gene (VD1) of *Chlamydia trachomatis* were tested in NASBA™. Following transcription, the appropriate primer mixture was added directly to the transcription reaction to give a final concentration in a 25 µl volume of 0.2 µM P1, 0.2 µM P2 and 15% (v/v) DMSO.

5 The reactions were heated at 65°C for 2 minutes and then transferred to 40°C. After 2 minutes at 40°C, a NASBA™ enzyme mixture containing 8 units AMV reverse transcriptase, 0.2 unit RNase H, 40 units T7 RNA polymerase and 100 µg/ml BSA was added to each reaction. The final reaction volume was adjusted to 25 µl with H₂O and the reactions were incubated at 40°C for an additional 90 minutes. Parallel NASBA™ reactions were performed with P1-primed material and neat material at similar concentrations.

Following amplification, a 5 µl aliquot of each reaction was analyzed by Northern blot hybridization. Specific amplification from PL1 and VD1 primers was observed from 10 pg and 1 pg of untreated total nucleic acids (neat) respectively (Figure 6 I, lanes A6-7 and Figure 6 II, lanes A6-7) likely due to RNA already contained in the sample. However, after transcription with *Escherichia coli* RNA polymerase, specific amplification for both PL1 and VD1 primers was obtained from 100 fg of total nucleic acids (Figure 6 I, lanes C2-3 and Figure 6 II, lanes C4-5) which was similar to the amplification when the P1-priming procedure for DNA was used (Figure 6 I, lanes B2-3 and Figure 6 II, lanes B4-5).

In Figure 6, the following lanes have the following material:

	A	-	untreated total nucleic acids
	B	-	P1-primed DNA
25	C	-	<i>Escherichia coli</i> RNA polymerase RNA from DNA
	1	-	no template
	2,3	-	10 fg total nucleic acids
	4,5	-	100 fg total nucleic acids
	6,7	-	1 pg total nucleic acids
30	8,9	-	10 pg total nucleic acids

Example 6 Direct amplification in NASBA™ of DNA transcribed with *Escherichia coli* RNA polymerase using a 2-step versus a 3-step procedure and a single reaction vessel.

5 Example 3 describes a 3-step procedure using 2 separate reaction vessels for the amplification of *Escherichia coli* RNA polymerase generated transcripts from DNA in NASBA™. Example 4, on the other hand, describes a 3-step procedure for performing the same task which uses a single reaction vessel.

10 In this example, the 3-step procedure using a single reaction vessel is replaced by a 2-step procedure using a single reaction vessel. That is, instead of the addition of a primer mixture to the primary transcription reaction as in example 4, DMSO (final 20.83% (v/v)) was added to the primary transcription reaction, and primers 1 and 2 were combined with the
15 enzyme mixture, and added later. All primary transcription reactions in this example contained 10 ng of HGD and the amplification was performed using GM-CSF specific primers.

 In one pair of reactions (set A), the 3-step procedure described in Example 4 was performed to serve as a control. In a second pair of
20 reactions (set B), the final concentration of DMSO in the amplification reaction was adjusted to 18.75% (v/v) and the same 3-step procedure was used.

 In a third pair at reactions (set C), the primary transcription reaction as set out in Example 1 contained in addition 15% (v/v) DMSO and 5 pmoles of
25 primer 1 in a total volume of 18 µl. The reactions were incubated at 40°C for 30 minutes, heated to 65°C for 2 minutes and then placed at 40°C for 2 minutes. A standard enzyme mixture containing in addition 15% (v/v) DMSO and 5 pmoles of primer 2 was then added to each reaction tube. Amplification was allowed to proceed at 40°C for 90 minutes.

In a fourth pair of reactions (set D), the primary transcription reaction as set out in Example 1 contained in addition 20.83% (v/v) DMSO in a total volume of 18 μ l. The reactions were incubated at 40°C for 30 minutes, heated to 65°C for 2 minutes and then placed at 40°C. A standard enzyme mixture containing in addition 5 pmoles of each of primers 1 and 2 was added to each reaction tube. Amplification was allowed to proceed at 40°C for 90 minutes.

The products contained in 5 μ l aliquots of each of the amplification reactions were analyzed on an ethidium bromide stained agarose gel followed by Northern blot hybridization. The results for the different sets (A-D) of reactions are shown in Figure 7. The control 3-step procedure reactions worked as anticipated when the DMSO concentration was 15% (v/v) (Figure 7, lanes A2-3) but not 18.75% (v/v) (Figure 7, lanes B2-3).

One of the 2-step procedure (reaction set C2-3) gave little or no specific amplification (Figure 7, lanes C2-3) likely due to the presence of primer I in the primary transcription reaction. The second 2-step procedure where primer 1 and primer 2 were added with the enzyme mixture worked despite a DMSO concentration of 20.83% (v/v) in the primary transcription reaction (Figure 7, lanes D2-3). Thus, it is possible to perform the amplification of DNA directly in NASBA™ using an *Escherichia coli* RNA polymerase transcription protocol in a 2-step procedure and a single reaction vessel much like for RNA amplification. If the 65°C heating step prior to the addition of the enzyme mixture to the reactions is eliminated, rifampicin (see Example 2) must be added along with the enzyme mixture.

In Figure 7, the following lanes have the following material:

- | | | |
|---|---|--|
| A | - | 3-step single reaction vessel procedure in 15% DMSO |
| B | - | 3-step single reaction vessel procedure in 18.75% DMSO |
| C | - | 2-step single reaction vessel procedure with 15% DMSO and primer 1 in the primary transcription reaction |
| D | - | 2-step single reaction vessel procedure with 20.83% DMSO in the primary transcription reaction |

- 1 - no added template
 - 2,3 - 10 ng of HGD
-

5

Although preferred embodiments of the invention have been described in detail, it will be understood by those skilled in the art that variations may be made to the invention without departing from either the spirit of the invention or the scope of the appended claims.

10

REFERENCES

1. Boom, R. *et al.* 1990. J. Clin. Micro. 28: 495
- 5 2. Chamberlin, M.J., 1976. RNA polymerase Losick, R and Chamberlin, M., (eds). Cold Spring Harbor Laboratory
3. Kacian *et al.* United States Patent No. 5,399,491
4. Malek *et al.* United States Patent Nos. 5,130,238 and 5,409,818
5. Mullis. United States Patent Nos. 4,683,195 and 4,683,202
- 10 6. Ovchinnikov, Y.A. *et al.*, 1977. FEBS Lett. 76: 108
7. Sambrook, J. *et al.*, 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor, NY: CSH Laboratory Press.
8. Sooknanan, R. *et al.*, 1993. Experimental Hematology 21: 1719.

I claim:

1. The use of a eukaryotic or prokaryotic DNA-directed RNA polymerase of a class that synthesizes cellular RNA, in a process for the amplification of a specific nucleic acid sequence.
2. The use of *Escherichia coli* RNA polymerase in a process for the amplification of a specific nucleic acid sequence.
3. The use of the polymerase as set out in Claim 1 or Claim 2, further comprising the use of an inhibitor of such polymerase.
4. The use of the polymerase as set out in Claim 1 or Claim 2, wherein the amplification is in vitro amplification selected from a group consisting of amplification of RNA, amplification of DNA, or amplification of RNA and DNA.
5. A process for the amplification of a specific nucleic acid sequence, comprising the steps of:
 - (A) providing in one or more reaction vessels reagents comprising,
 - (i) a DNA first template,
 - (ii) a first RNA polymerase which is a eukaryotic or prokaryotic RNA polymerase, said polymerase being of a class that synthesizes cellular RNA,
 - (iii) ribonucleoside triphosphates;
 - (iv) deoxyribonucleoside triphosphates,
 - (v) a first oligonucleotide primer, comprising a plus sequence of a promoter recognised by a second RNA polymerase,
 - (vi) a second oligonucleotide primer,

- (vii) a second RNA polymerase which is a DNA-directed RNA polymerase that recognizes said promoter,
- (viii) an RNA-directed DNA polymerase,
- (ix) a DNA-directed DNA polymerase,
- (x) a ribonuclease that hydrolyzes RNA of an RNA-DNA hybrid without hydrolyzing single or double-stranded RNA or DNA,

under conditions such that,

- (1) such first RNA polymerase uses said DNA first template to synthesize an RNA first template which comprises said specific nucleic acid sequence or a sequence complementary to said specific nucleic acid sequence,
- (2) said first oligonucleotide primer hybridizes to said RNA first template,
- (3) said RNA-directed DNA polymerase uses said RNA first template to synthesize a DNA second template by extension of said first oligonucleotide primer and thereby forms an RNA-DNA hybrid intermediate,
- (4) said ribonuclease hydrolyzes RNA which comprises said RNA-DNA hybrid intermediate,
- (5) said second oligonucleotide primer hybridizes to said DNA second template,
- (6) said DNA-directed DNA polymerase uses said second oligonucleotide primer and said DNA second template to synthesize a functional promoter recognized by said second RNA polymerase,

and

- (7) said second RNA polymerase recognizes said functional promoter and transcribes said DNA second template, thereby providing copies of an RNA second template,

and thereafter a cycle ensures wherein

- 5 (1) said second oligonucleotide primer hybridizes to said RNA second template,
- (2) said RNA-directed DNA polymerase uses said RNA second template to synthesize a DNA third template by extension of said second oligonucleotide primer and thereby forms an RNA-DNA hybrid intermediate,
- 10 (3) said ribonuclease hydrolyzes RNA of said RNA-DNA hybrid intermediate,
- (4) said first oligonucleotide primer hybridizes to said DNA third template,
- 15 (5) said DNA-directed DNA polymerase uses said first oligonucleotide primer as template to synthesize a functional promoter recognized by said second RNA polymerase by extension of said DNA third template,
- and
- 20 (6) said second RNA polymerase recognizes said functional promoter and transcribes said DNA third template, thereby providing copies of said RNA second template,

and thereafter

- (B) maintaining said conditions for a time sufficient to achieve
- 25 a desired amplification of said specific nucleic acid sequence or of a sequence complementary to said specific nucleic acid sequence.

6. A process for the amplification of a specific nucleic acid sequence, comprising the steps of:

- (A) providing reagents comprising at least,
 - (i) a DNA first template,
 - 5 (ii) a first RNA polymerase which is a eukaryotic or prokaryotic RNA polymerase, said polymerase being of a class that synthesizes cellular RNA,
 - (iii) ribonucleoside triphosphates;

under conditions such that such first RNA polymerase uses said DNA first template to synthesize an RNA first template which comprises said specific nucleic acid sequence or a sequence complementary to said specific nucleic acid sequence,

- (B) providing in one or more steps reagents comprising,
 - (i) a first oligonucleotide primer, comprising a plus sequence of a promoter recognised by a second RNA polymerase,
 - 15 (ii) a second oligonucleotide primer,
 - (iii) a second RNA polymerase which is a DNA-directed RNA polymerase that recognizes said promoter,
 - (iv) an RNA-directed DNA polymerase,
 - 20 (v) a DNA-directed DNA polymerase,
 - (vi) a ribonuclease that hydrolyzes RNA of an RNA-DNA hybrid without hydrolyzing single or double-stranded RNA or DNA,
 - (vii) ribonucleoside and deoxyribonucleoside triphosphates,

25 and

under conditions such that,

- (1) said first oligonucleotide primer hybridizes to said RNA first template,
- (2) said RNA-directed DNA polymerase uses said RNA first template to synthesize a DNA second template by

extension of said first oligonucleotide primer and thereby forms an RNA-DNA hybrid intermediate,

(3) said ribonuclease hydrolyzes RNA of said RNA-DNA hybrid intermediate,

5 (4) said second oligonucleotide primer hybridizes to said DNA second template,

(5) said DNA-directed DNA polymerase uses said second oligonucleotide primer and said DNA second template to synthesize a functional promoter recognized by said
10 second RNA polymerase,

and

(6) said second RNA polymerase recognizes said functional promoter and transcribes said DNA second template, thereby providing copies of an RNA second template,

15 and thereafter a cycle ensues wherein

(1) said second oligonucleotide primer hybridizes to said RNA second template,

(2) said RNA-directed DNA polymerase uses said RNA second template to synthesize a DNA third template by extension of said second oligonucleotide primer and thereby forms an RNA-DNA hybrid intermediate,
20

(3) said ribonuclease hydrolyzes RNA of said RNA-DNA hybrid intermediate,

(4) said first oligonucleotide primer hybridizes to said DNA third template,
25

(5) said DNA-directed DNA polymerase uses said first oligonucleotide primer as template to synthesize a functional promoter recognized by said second RNA polymerase by extension of said DNA third template,

5 and

(6) said second RNA polymerase recognizes said functional promoter and transcribes said DNA third template, thereby providing copies of said RNA second template,

and thereafter

10 (C) maintaining said conditions for a time sufficient to achieve a desired amplification of said specific nucleic acid sequence or of a sequence complementary to said specific nucleic acid sequence.

7. A process according to Claim 5 or Claim 6, wherein said first RNA
15 polymerase is one selected from a group consisting of *Escherichia coli* RNA polymerase, RNA polymerase of *Bacillus*, RNA polymerase of *Archae* bacteria, RNA polymerase I, RNA polymerase II and RNA polymerase III.

8. A process according to Claim 6, wherein Step (A) further
20 comprises providing deoxyribonucleoside triphosphates.

9. A process according to Claim 5 or Claim 6, further comprising providing an inhibitor of said first RNA polymerase.

25 10. A process according to Claim 9, wherein such inhibitor is rifampicin.

11. A process according to Claim 6, wherein Step (A) is followed by heating said reagents and said RNA first template before Step (B).

12. A process according to Claim 11, wherein said reaction medium is heated to about 65°C.
13. A process according to Claim 5 or Claim 6, further comprising
5 providing an alkylated sulfoxide and a suitable carrier protein.
14. A process according to Claim 13 wherein said alkylated sulfoxide is dimethylsulfoxide (DMSO) and wherein said carrier protein is bovine serum albumin (BSA).
- 10 15. A process according to Claim 7, wherein said *Escherichia coli* RNA polymerase is provided at a concentration in the range of 0.04 -0.2 units per µl.
- 15 16. A process according to Claim 9, wherein inhibitor is provided at a concentration in the range of 10-100 µg per ml.
17. A process according to Claim 5 or Claim 6, wherein in Step (A), said DNA first template is double-stranded DNA.
- 20 18. A process according to Claim 5 or Claim 6, wherein in Step (A), said DNA first template is single-stranded DNA.
19. A process according to Claim 5 or Claim 6, wherein said first
25 oligonucleotide primer further comprises a plus sequence of a transcription initiation site for said second RNA polymerase, said plus sequence of said transcription initiation site being operatively linked to said plus sequence of said promoter.

20. A process according to Claim 19, wherein said second RNA polymerase is bacteriophage T7 RNA polymerase and wherein said plus sequence of a transcription initiation site and said plus sequence of said promoter together comprise the nucleotide sequence

5

5' - AATTCTAATACGACTCACTATAGGGAGA - 3'

21. A process according to Claim 5 or Claim 6, wherein said process further comprises, a step of monitoring said reaction medium for consumption
10 of any of said first primer, second primer, and ribonucleoside and deoxyribonucleoside triphosphates for accumulation of any product of said cycle.

22. A process according to Claim 21, wherein monitoring step
15 comprises detecting said specific nucleic acid sequence or a sequence complementary to said sequence.

23. A process according to Claim 22, wherein said monitoring step
comprises detecting said sequence using a nucleic acid probe.

20

24. A process according to Claim 22, wherein said monitoring step
comprises detecting said sequence using restriction endonucleases and
electrophoretic separation.

25. A process according to Claim 21, wherein said monitoring step
25 comprises monitoring the accumulation of said RNA second template.

26. A process according to Claim 21, wherein said monitoring step
comprises monitoring the accumulation of said DNA second template.

30

27. A process according to Claim 21 wherein said monitoring step comprises monitoring DNA containing a functional promoter recognized by said second RNA polymerase.
- 5 28. A process according to Claim 21, wherein said monitoring step comprises monitoring the accumulation of said RNA-DNA hybrid intermediate.
29. A process according to Claim 21 wherein said monitoring step further comprises comparing consumption of any of said first primer, second
10 primer, ribonucleoside and deoxyribonucleoside triphosphates or accumulation of any product of said cycle with a value representing consumption of said reagent or accumulation of said product in said reaction medium in the absence of said specific nucleic acid sequence and said sequence complementary thereto.
- 15 30. A process according to Claim 5 or Claim 6, further comprising providing a single reaction vessel for said steps.
31. A process according to Claim 5 or Claim 6, wherein said
20 ribonuclease comprises calf thymus ribonuclease H.
32. A process according to Claim 5 or Claim 6, wherein said first oligonucleotide primer or said second oligonucleotide primer is bound reversibly to an immobilized support.
- 25 33. A process according to Claim 5 or Claim 6, wherein said DNA-directed RNA polymerase is a bacteriophage RNA polymerase.
34. A process according to Claim 33, wherein said DNA-directed
30 RNA polymerase is bacteriophage T7 RNA polymerase.

35. A process according to Claim 33, wherein said DNA-directed RNA polymerase is bacteriophage T3 polymerase.

36. A process according to Claim 33, wherein said DNA-directed
5 RNA polymerase is bacteriophage Φ II polymerase.

37. A process according to Claim 33, wherein said DNA-directed RNA polymerase is *Salmonella* bacteriophage sp6 polymerase.

10 38. A process according to Claim 33, wherein said DNA-directed RNA polymerase is *Pseudomonas* bacteriophage gh-1 polymerase.

39. A process according to Claim 5 or Claim 6, wherein said RNA-directed DNA polymerase is a retrovirus reverse transcriptase.

15

40. A process according to Claim 5 or Claim 6, wherein said retrovirus reverse transcriptase is avian myeloblastosis virus polymerase.

41. A process according to Claim 5 or Claim 6, wherein said
20 retrovirus reverse transcriptase is a Moloney murine leukemia virus polymerase.

42. A process according to Claim 5 or Claim 6, wherein said retrovirus reverse transcriptase is *Escherichia coli* ribonuclease H.

25

43. A process according to Claim 5 or Claim 6, wherein said DNA-directed DNA polymerase lacks exonuclease activity.

44. A process according to Claim 5 or Claim 6, wherein all DNA
30 polymerases in said reaction medium lack DNA exonuclease and DNA endonuclease activity.

45. A process according to Claim 5 or Claim 6, wherein said DNA-directed DNA polymerase is avian myeloblastosis virus polymerase.
46. A process according to Claim 5 or Claim 6, wherein said DNA-directed DNA polymerase is DNA polymerase α or DNA polymerase β .
47. A process according to Claim 5 or Claim 6, wherein said DNA-directed DNA polymerase is calf thymus DNA polymerase.
48. A process according to Claim 5 or Claim 6, wherein Step (C) comprises maintaining said conditions for a time between 30 minutes and 4 hours.
49. A process according to Claim 5 or Claim 6, further comprising the steps of ligating a DNA product of said cycle into a cloning vector and then cloning said DNA product.
50. A process according to Claim 5 or Claim 6, further comprising the step of expressing a product encoded by any DNA product of said cycle in an expression system.
51. A kit for amplifying nucleic acid sequences, comprising one or more receptacles containing
- (a) a first RNA polymerase which is a DNA-directed RNA polymerase which synthesizes cellular RNA,
 - (b) ribonucleoside triphosphates,
 - (c) deoxyribonucleoside triphosphates,
 - (d) a first oligonucleotide primer comprising a plus sequence of a promoter recognized by a second RNA polymerase,
 - (e) a second oligonucleotide primer,

- 5 (f) a second RNA polymerase which is a DNA-directed RNA polymerase that recognizes said promoter,
(g) an RNA-directed DNA polymerase,
(h) a DNA-directed DNA polymerase, and
(i) a ribonuclease that hydrolyzes RNA of an RNA-DNA hybrid without hydrolyzing single- or double-stranded RNA or DNA.

10 52. A kit as set forth in Claim 51, wherein said first RNA polymerase is *Escherichia coli* RNA polymerase.

53. A kit as set forth in Claim 51, further comprising a receptacle containing an inhibitor of *Escherichia coli* RNA polymerase.

15 54. A kit as set forth in Claim 53, wherein the inhibitor is rifampicin.

55. A kit as set forth in Claim 51, further comprising a receptacle containing an alkylated sulfoxide and a receptacle containing a suitable carrier protein.

20




FIG.1.




FIG. 2.

3/8




FIG.3 A.

SUBSTITUTE SHEET

4/8




FIG. 3B.

5/8

Ethidium bromide gel




FIG.4A.

Northern-blot

1 2 3 4 5 6 7 8 9 10



FIG.4B.

6/8

I. GM-CSF

A							B							C						
1	2	3	4	5	6	7	1	2	3	4	5	6	7	1	2	3	4	5	6	7



II. G3PDH


A							B							C						
1	2	3	4	5	6	7	1	2	3	4	5	6	7	1	2	3	4	5	6	7



FIG. 5.

7/8

I. PL1



II. VD1




FIG.6.

SUBSTITUTE SHEET

8/8




FIG. 7.

INTERNATIONAL SEARCH REPORT

 International Application No
 PCT/CA 95/00423

 A. CLASSIFICATION OF SUBJECT MATTER
 IPC 6 C12Q1/68 C12P19/34

C07H21/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO,A,91 04340 (CAMBRIDGE BIOTECH CORP) 4 April 1991 see page 17, line 16 - page 18, line 10 and Fig. 7, sheet 10/10; pages 37 & 38. ---	1,2, 4-12, 17-52
A	WO,A,91 02818 (CANGENE) 7 March 1991 see the whole document ---	1-55
A	WO,A,91 02814 (AKZO N.V.) 7 March 1991 see the whole document ---	1-55
A	WO,A,91 01384 (GEN-PROBE, INC.) 7 February 1991 see the whole document -----	1-55

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

26 October 1995

Date of mailing of the international search report

05.01.96

Name and mailing address of the ISA

 European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+ 31-70) 340-3016

Authorized officer

Osborne, H

INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 95/00423

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9104340	04-04-91	NONE	
WO-A-9102818	07-03-91	US-A- 5130238	14-07-92
		AU-B- 647411	24-03-94
		AU-B- 6336590	03-04-91
		CA-A- 2065003	24-02-91
		EP-A- 0487628	03-06-92
		JP-T- 4507197	17-12-92
WO-A-9102814	07-03-91	AT-T- 106948	15-06-94
		DE-D- 3850093	14-07-94
		DE-T- 3850093	03-11-94
		EP-A- 0329822	30-08-89
		ES-T- 2053648	01-08-94
		JP-A- 2005864	10-01-90
		US-A- 5409818	25-04-95
WO-A-9101384	07-02-91	AU-B- 650622	30-06-94
		AU-B- 6166390	22-02-91
		AU-B- 7415694	24-11-94
		CA-A- 2020958	12-01-91
		EP-A- 0408295	16-01-91
		JP-T- 4500759	13-02-92
		US-A- 5399491	21-03-95